- Home
- Publications
- Publication Search
- Publication Details
Title
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 8, Pages 1822
Publisher
MDPI AG
Online
2019-04-13
DOI
10.3390/ijms20081822
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrative Pharmacology: Advancing Development of Effective Immunotherapies
- (2018) Mohammad Tabrizi et al. AAPS Journal
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
- (2018) Yuan Zhang et al. Nature Communications
- Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy
- (2018) Akihiro Hosoi et al. Scientific Reports
- S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity
- (2018) Jinhua Zhang et al. OncoImmunology
- Therapeutic vaccination with 4–1BB co-stimulation eradicates mouse acute myeloid leukemia
- (2018) Daniel Kerage et al. OncoImmunology
- Cancer immunologists scoop medicine Nobel prize
- (2018) Heidi Ledford et al. NATURE
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
- (2018) S. Michael Chin et al. Nature Communications
- The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response
- (2017) Nancy D. Marín et al. TUBERCULOSIS
- Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma
- (2017) Sara J. McKee et al. Cancer Immunology Research
- Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
- (2017) M. Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies
- (2015) Dass S Vinay et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- S100A4 promotes liver fibrosis via activation of hepatic stellate cells
- (2015) Lin Chen et al. JOURNAL OF HEPATOLOGY
- High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma
- (2015) Cheol Lee et al. PATHOLOGY RESEARCH AND PRACTICE
- NKT cell-targeted vaccination plus anti-4–1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma
- (2015) Takumi Kobayashi et al. OncoImmunology
- Detection of The TNFSF Members BAFF, APRIL, TWEAK and Their Receptors in Normal Kidney and Renal Cell Carcinomas
- (2015) Vassiliki Pelekanou et al. Analytical Cellular Pathology
- Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
- (2014) Vanessa Gauttier et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
- (2014) Shravan Madireddi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Involvement of the 4-1BB/4-1BBL Pathway in Control of Monocyte Numbers by Invariant NKT Cells
- (2014) S. L. Cole et al. JOURNAL OF IMMUNOLOGY
- Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers
- (2014) Jennifer A. Westwood et al. LEUKEMIA RESEARCH
- A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis and are targets of metastasis-inducing S100A4
- (2014) M T Hansen et al. ONCOGENE
- Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands
- (2014) Ling Yi et al. PLoS One
- Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice
- (2014) Jennifer A. Westwood et al. PLoS One
- The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling
- (2014) Inge Verbrugge et al. RADIATION RESEARCH
- Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes
- (2014) Karsten A Pilones et al. Journal for ImmunoTherapy of Cancer
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
- (2013) A. Morales-Kastresana et al. CLINICAL CANCER RESEARCH
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes
- (2013) I. Martinez-Forero et al. JOURNAL OF IMMUNOLOGY
- Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
- (2013) Min Dai et al. JOURNAL OF IMMUNOTHERAPY
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
- (2013) Benjamin A. H. Jensen et al. PLoS One
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
- (2013) Aizea Morales-Kastresana et al. Journal for ImmunoTherapy of Cancer
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer
- (2012) L. B. John et al. CANCER RESEARCH
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
- (2012) Ester Simeone et al. Journal of Immunotoxicology
- Immunotherapy of Cancer with 4-1BB
- (2012) D. S. Vinay et al. MOLECULAR CANCER THERAPEUTICS
- Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12
- (2012) José I Quetglas et al. MOLECULAR THERAPY
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
- (2012) Pontus Boström et al. NATURE
- The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
- (2012) Asís Palazón et al. Cancer Discovery
- Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory
- (2011) Jang-June Park et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses
- (2011) Shannon E. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
- (2011) A. Palazon et al. CANCER RESEARCH
- T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy
- (2011) Laura M. Snell et al. IMMUNOLOGICAL REVIEWS
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TNF superfamily in inflammatory disease: translating basic insights
- (2011) Michael Croft et al. TRENDS IN IMMUNOLOGY
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
- (2010) H. Narazaki et al. BLOOD
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
- (2010) Carol M Lee et al. BMC CANCER
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
- Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice
- (2008) Seong-A Ju et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search